Bioventus (BVS)
(Delayed Data from NSDQ)
$7.17 USD
+0.10 (1.41%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.16 -0.01 (-0.14%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.17 USD
+0.10 (1.41%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.16 -0.01 (-0.14%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth D Momentum C VGM
Zacks News
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
by Zacks Equity Research
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
Encompass Health (EHC) Expands in Louisville With New Rehab Unit
by Zacks Equity Research
Encompass Health (EHC) and Baptist Health inaugurate a 40-bed inpatient rehabilitation hospital in Louisville, enhancing regional care and expanding EHC's network to 163 facilities.
Here's Why Investors Must Hold on to Centene (CNC) Stock Now
by Zacks Equity Research
Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.
Compelling Reasons to Hold on to Cigna (CI) Stock for Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of improved pharmacy revenues in its Evernorth unit. Solid cash-generating abilities also enable it to tactically deploy capital.
Here's Why You Should Consider Buying Bioventus (BVS) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.
J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
by Zacks Equity Research
J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.
Humana (HUM) Partners With UAB to Boost Care for MA Members
by Zacks Equity Research
Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
by Zacks Equity Research
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
by Zacks Equity Research
Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
by Zacks Equity Research
J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.
5 Small Drug Stocks to Buy From a Recovering Industry
by Kinjel Shah
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
Here's Why You Should Retain Centene (CNC) Stock for Now
by Zacks Equity Research
Centene (CNC) remains well-poised for growth on the back of sound growth in membership, divestitures and a growing cash balance.
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -182.76% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.
3 Value Medical Stocks to Buy for Safety Amid Market Volatility
by Indrajit Bandyopadhyay
We have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS.
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -30.77% and 3.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 100% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Durect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 5th
by Zacks Equity Research
BVS, BFAM and ESTE have been added to the Zacks Rank #5 (Strong Sell) List on April 5, 2023.
Journey Medical Corporation (DERM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -62.16% and 4.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -500% and 6.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Bioventus (BVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bioventus (BVS) stock based on the movements in the options market lately.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?